According to filings with the U.S. Securities and Exchange Commission, Blaze Bioscience is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Blaze Bioscience
Blaze Bioscience, Inc. is a privately held biotechnology company dedicated to improving the lives of cancer patients, starting with kids undergoing brain cancer surgery. By leveraging our Tumor Paint technology, including the CANVAS Imaging system and our CDP Discovery Platform, our goal is to make the detection, removal, and treatment of all cancers sensitive, reliable, and accessible, especially early-stage cancers where cure may still be possible.

To learn more about Blaze Bioscience, visit http://www.blazebioscience.com/
Blaze Bioscience Linkedin Page: https://www.linkedin.com/company/blaze-bioscience/

Contact:
Steven Daly, Chief Executive Officer
206-535-8144
https://www.linkedin.com/in/srdaly/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.